Post

New research · Urology
Annals of surgical oncology · 1d
Cohort studyAnnals of surgical oncology · 2026

An Integrated Cell-Death Program Defines Aggressive Prostate Cancer by Coupling Ezrin to the Hippo-YAP/TAZ Axis.

Xing Luo, Zeyu Huang, Min Deng … Ji Zheng
Read paper
UrologyCohort study

High AEN score is associated with a higher rate of biochemical recurrence in prostate cancer.

An Integrated Cell-Death Program Defines Aggressive Prostate Cancer by Coupling Ezrin to the Hippo-YAP/TAZ Axis.

Xing Luo et al. · Annals of surgical oncology · 2026
Background

Prostate cancer (PCa) exhibits highly heterogeneous clinical outcomes, underscoring the need for biomarkers that more closely reflect tumor biology.

Methods

We constructed 14 PCD prognostic models in a training cohort (GSE116918, n = 248), integrated the top three (apoptosis, entosis, necroptosis) into an AEN score, and validated in two independent cohorts in PCa.

n = 248
HR = 8.02
Results
a high AEN score strongly predicts a higher risk of prostate cancer returning
n = 248
More results

High‑AEN tumors exhibited a non‑inflamed TME, predicted immunotherapy resistance, yet increased chemosensitivity.

EZR was nominated as a causal driver; knockdown of EZR suppressed proliferation, migration, and tumor growth via YAP/TAZ dysregulation.

“
Conclusion

The AEN score is a robust prognostic tool linking PCD activity to PCa aggressiveness and immune evasion. EZR emerges as a functional effector and potential therapeutic target acting through Hippo signaling in PCa.

Read paper
0 comments

No comments yet. Be the first.

Related papers

LatestFoundational
Cohort Study
HR 1.87
lower muscle quality means nearly twice the risk of dying from advanced prostate cancer
Cross-sectional
71.8%
most urologists never used a standard survey to assess stent symptoms
Cohort Study
SIR 1.67
young bladder cancer survivors have a higher risk of developing second cancers compared to the general population
Cohort Study
98%
98% of patients had no significant rectocele after laparoscopic double sacrocolpopexy.
Cohort Study
OR 0.10
Beyond 4000 J/ml, the odds of reintervention are 90% lower.
Randomized Trial
hazard ratio 0·67
pirarubicin instillation led to a lower risk of recurrence compared to observation
Study
3,216
This many specific enhancers were found in prostate cancer cells, not normal cells.
Case-control
OR = 4.23
Higher triglycerides linked to higher odds of prostate cancer (odds, not risk)